drugset / Trial / NCT07463599
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).
Timeline
- Start
- 2026-02-17
- Primary completion
- 2029-01
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tegavivint | Small molecule | 5 mg/kg | Intravenous |
| Subject | Tegavivint | Small molecule | 6.5 mg/kg | Intravenous |
| Subject | Tegavivint | Small molecule | 8 mg/kg | Intravenous |
| Subject | Tegavivint | Small molecule | 10 mg/kg | Intravenous |